{
    "project_id": "170794",
    "broad_study_type": "other",
    "narrow_study_type": "drug_development",
    "trial_phase": "preclinical",
    "observational_timeframe": "N/A",
    "justification": "elucidate the role and mechanism of action cIAP1 in NF-kappaB signaling in skeletal muscle, and evaluate its contribution to the pathology of muscular dystrophy. Moreover, as we have in hand several drugs that potently and specifically target cIAP1 for destruction, we will evaluate the therapeutic potential of these drugs in the treatment of muscular dystrophy",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "This discovery has raised the exciting possibility that cIAP1 may be a potential therapeutic target for various muscle diseases that rely on NF-kappaB signaling.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "unclear",
    "gender_focus": "unclear",
    "vulnerable_populations": "no",
    "rare_disease": "yes",
    "population_description": "N/A",
    "intervention_category": "drug",
    "intervention_name": "cIAP1 targeting drugs",
    "control_type": "experimental_control",
    "dose_response": "unclear",
    "combination_therapy": "no",
    "personalized_medicine": "yes",
    "primary_outcome": "therapeutic potential of cIAP1 targeting drugs in muscular dystrophy",
    "primary_outcome_type": "biomarker",
    "safety_focus": "yes",
    "quality_of_life": "no",
    "biomarker_endpoints": "yes",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "no",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "no",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "yes",
    "ethics_focus": "no",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "neuromuscular",
    "disease_stage": "unclear",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "medium_term",
    "multicenter": "no",
    "healthcare_setting": "laboratory",
    "disease_area": "muscular dystrophy, inflammatory myopathies, skeletal muscle atrophy",
    "methodology_innovation": "investigating cIAP1 as a therapeutic target for muscular dystrophy through its role in NF-kappaB signaling",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 